Stocktoria
Revolution Medicines, Inc. RVMD
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-02-13
Revolution Medicines, Inc. statistics & valuation
Market cap$38.7B
P / B23.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -4207.1% | -730.0% | -639.7% |
| Net margin | — | — | -3768.3% | -703.0% | -636.6% |
| FCF margin | — | — | -3094.1% | -664.8% | -523.0% |
| Return on assets | -48.0% | -23.5% | -21.2% | -30.6% | -25.4% |
| Return on equity | -69.3% | -26.5% | -23.9% | -36.3% | -31.0% |
| Current ratio | 7.14 | 14.20 | 13.06 | 10.65 | 9.77 |
| Revenue growth | — | -100.0% | -67.3% | 20.4% | -31.6% |
Source: SEC EDGAR filings · CIK 0001628171 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.